EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

Xiujuan Chang, Yinying Li, Chao Sun, Xiaodong Li, Wenjuan Du, Qinghua Shang, Laicheng Song, Qinghua Long, Qin Li, Huabao Liu, Jing Wang, Zujiang Yu und 7 weitere

Journal of Gastroenterology · 2023-05 · 58 (5) · 481-493

DOI: 10.1007/s00535-023-01970-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 16.03.2023. Verfasst von Xiujuan Chang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Major Science and Technology Special Project of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Progressive hepatic fibrosis leads to hepatocellular carcinoma (HCC) and decompensated cirrhosis. The aim of this study was to identify the high-risk population for progressive hepatic fibrosis and the incidence of HCC and decompensated cirrhosis in chronic hepatitis B (CHB) patients with antiviral therapy. METHODS: The data came from a multicenter, center-randomized, double-blind clinical trial that analyzed only patients in the ETV-treated arm. There was 156 hepatitis B e antigen (HBeAg)-positive and 135 HBeAg-negative patients in 14 institutions. The primary endpoint was fibrosis reversal on 72-week Entecavir (ETV) treatment. The 7-year cumulative incidence of HCC and decompensated cirrhosis were analyzed. Multivariate logistic and LASSO regression analyses were used to screen variables associated with fibrosis reversal. RESULTS: 86/156 (55%) HBeAg-positive and 58/135 (43%) HBeAg-negative patients achieved fibrosis reversal on 72-week ETV treatment. Average age was 43 years, 203 (69.8%) was male, and 144 (49.5%) patients had cirrhosis. Age ≥ 40 years (OR: 0.46, 95% CI 0.23-0.93) and HBcrAg ≥ 8.23 log U/ml (OR: 2.72, 95% CI 1.33-5.54) in HBeAg-positive patients and HBV genotype C (OR: 0.44, 95% CI 0.21-0.97) in HBeAg-negative patients were independent factors of fibrosis reversal. It was confirmed in patients with cirrhosis. After 7-year ETV treatment, seven (4.5%) HBeAg-positive patients occurred HCC or decompensated cirrhosis, including four patients with age ≥ 40 years and six with HBcrAg 8.23log U/ml, while twelve (8.9%) HBeAg-negative patients occurred, including eleven with HBV genotype C. CONCLUSIONS: HBeAg-positive patients with a low HBcrAg level or old age, and HBeAg-negative patients with HBV genotype C tended to develop progressive hepatic fibrosis and had a high incidence of HCC and decompensated cirrhosis, even on ETV treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicCarcinoma, HepatocellularLiver NeoplasmsHumansMaleAdultHepatitis B virusAntiviral AgentsHepatitis B e AntigensLiver CirrhosisDNA, Viral

Stichwörter der Autor:innen

HBcrAgHBeAgHBsAgHepatic fibrosisHepatocellular carcinoma

Substanzen

Antiviral AgentsHepatitis B e AntigensDNA, Viral

Autor:innen und Institutionen

  • Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Chinese PLA Medical School, Beijing, 100853, China.
  • Department of Research for Clinical Medicine, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Discipline and Degree Division, the Graduate School of the PLA General Hospital, Beijing, 100853, China.
  • Center of Therapeutic Liver Disease, the 88th Hospital of Chinese PLA, Taian, 271000, Shandong Province, China.
  • Traditional Chinese Medicine Hospital of Taihe, Taihe, 400038, Anhui Province, China.

Förderung

  • Natural Science Foundation of Beijing Municipality
  • Major Science and Technology Special Project of China

Zitieren

APA

Chang, X., Li, Y., Sun, C., Li, X., Du, W., Shang, Q., Song, L., Long, Q., Li, Q., Liu, H., Wang, J., Yu, Z., Li, J., Xiao, G., Li, L., Chen, L., Tan, L., Chen, Y., & Yang, Y. (2023). High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. Journal of Gastroenterology, 58(5), 481-493. https://doi.org/10.1007/s00535-023-01970-3

Vancouver

Chang X, Li Y, Sun C, Li X, Du W, Shang Q, et al. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. Journal of Gastroenterology. 2023;58(5):481-493. doi:10.1007/s00535-023-01970-3

BibTeX
@article{Chang2023,
  author = {Chang, Xiujuan and Li, Yinying and Sun, Chao and Li, Xiaodong and Du, Wenjuan and Shang, Qinghua and Song, Laicheng and Long, Qinghua and Li, Qin and Liu, Huabao and Wang, Jing and Yu, Zujiang and Li, Jiang and Xiao, Guangming and Li, Li and Chen, Liang and Tan, Lin and Chen, Yongping and Yang, Yongping},
  title = {High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy},
  journal = {Journal of Gastroenterology},
  year = {2023},
  volume = {58},
  number = {5},
  pages = {481--493},
  doi = {10.1007/s00535-023-01970-3}
}
Kostenlos starten →